Now we have to fight Kramer every night. The fool went to 50% cash and now he is going to have to watch the market skyrocket when the Dems and Republicans agree on some small deal. Now he's suddenly Bearish and he will spend his time on TV talking about valuations because he jumped out. Revers book talking...
AMC is looking good for a buy coming out of the dip, yeah. I can't trade it today, no day trades, or I would pick up a few hundred at the bottom reversal. Which could be in the next few minutes. Big opening selloff at the bell. My WAG is it will try the $6.50 level and end the day just a bit below that, try it again Monday and break on through.
Grand Canyon upgraded to Buy from Neutral at Sidoti 08:39 LOPE Sidoti analy - When this moves it moves! Chinese Co I think. The locations off the main roads of CB does make it attractive for investment. The key is drive thru really helps & I do not think that's the set up at CB it's more a night out to eat... BUT THAT's WHAT'S GOING TO COME Back eventually. There was the terrible news story yesterday about people with Covid being more likely to have eaten out-- non scientific but scary. But lets get past the election and the vaccine and we are all just sitting around a table at CrackerBarell talking about the way Trump left office is such disgrace. Do they serve booze?
I AM NOT SEEING THE DIVIDEND! THEY MUST OF SHELVED IT... Shares ofCracker Barrel Old Country Store, Inc.CBRL have been negatively impacted by the coronavirus pandemic. Notably, the company is witnessing dismal traffic due to social-distancing protocols. Also, rise in labor costs along with high debt levels are adding to the negatives. So far this year, shares of the company have declined 11.2% against the industry’s 6.9% growth. During the fiscal third quarter (ended May 1, 2020), the company’s comparable restaurant sales and comparable store retail sales declined 41.7% and 45.5%, respectively, on a year-over-year basis. Moreover, the company’s results in fiscal fourth quarter are likely to have been impacted by the coronavirus pandemic. Although some of the restaurants have reopened their dining rooms, the company’s saw dismal traffic owing to social-distancing protocols, shelter-in-place orders and capacity restrictions. We believe that the coronavirus outbreak will further hurt traffic and sales in the coming quarters as well. Hummmm LOCO- I wonder if this guy tells his wife he has a job reviewing food places on the Net'
Thats like asking if Chik-Fil-A does. These are Christian/family oriented operations stoney... they don't want a bunch a damn loud drunks in there raising hell staggering around breaking things. Google an image of their gift-shops. Hell you can barely fit in the aisle. They make bank off those gift shops, prior to Covid the line to get seated wound through them. Bunch of crafty junk the wives buy and pay 3X too much. Like an Etsy showroom almost. EDIT oops.... well I guess they do. hmph. Never asked.
-- Watch Go daddy today. NEWS The First Pure-Play Psychedelic Drugs IPO Reveals Clues On Emerging Industry 04:17 PM ET 08/31/2020 Compass Pathways, which is developing a therapy that uses synthetic psilocybin, on Friday became the first pure-play psychedelic drug company to file for an IPO, a move that lent further insights intowhat shape a legal psychedelic drugs industry might take as bigger money moves into the space. The company is backed by billionaire investor Peter Thiel, who cofoundedPayPal(PYPL) and Palantir, and has developed a crystalline form of psilocybin — the mind-altering compound in magic mushrooms — called COMP360. Compass Pathways, based in London, intends to pair the administering of COMP360 with therapy for depression that persists despite other forms of treatment. If COMP360 is approved, Compass plans to market it toward health-care providers and clinic networks in the U.S. and Europe. Management is looking to raise up to $100 million, according to the filing on Friday. It would trade on the Nasdaq Global Market under the ticker CMPS. Yikes 3rd tier bok runners! Cowen, Evercore and Berenberg are the joint book-running managers for the IPO. Canaccord Genuity, which helped galvanize the cannabis industry's rush to the public markets, is serving as lead manager. The company is currently examining the safety and effectiveness of the COMP360 therapy in a Phase 2b trial of more than 200 such patients in 20 sites in North America and Europe. Researchers in that trial are exploring three dose sizes for the drug. Compass said it plans to report data from the tests late next year, the filing said. Compass last year completed a Phase I trial of the therapy on 89 volunteers. The FDA in 2018 gave breakthrough status to COMP360. The IPO filing noted that more than 320 million people around the world suffer from major depressive disorder. The FDA has OK'd other treatments using psychedelic drugs. The FDA last year approvedJohnson & Johnson's(JNJ) nasal spray Spravato, which uses a derivative of ketamine, for treatment-resistant depression. The agency this summer approved Spravato for people who are actively suicidal. How To Research Growth Stocks: Just Ask gummybearadvisors-! Significant Losses The first psychedelic drugs IPO filing comes as investors like hedge fund titan Steve Cohen and Bob Parsons, the founder ofGoDaddy(GDDY), put their support behind research into the effects of drugs like MDMA, also known as ecstasy or Molly.- Go Bob! But the Compass Pathways IPO filing, however, warned it had taken "significant losses," with more likely, and that the therapy will require "substantial additional funding." The company had a net loss of around $25 million over the first half of this year. Costs relating to testing and compliance drove those losses. As of June 30, its accumulated deficit was $62.4 million. Compass said it relies on third parties to make and supply the psilocybin used in COMP360, with no plans to build any manufacturing facilities. It said it faces "substantial competition" — from big pharma companies, universities and nonprofits — and has identified "material weaknesses" in its financial reporting protocols. The company noted that challenges remained in completing trials, training therapists and developing facilities for that training and other research. The costs making medications available to patients could be steep. Since psilocybin consumption isn't yet legal, regulatory scrutiny could be more intense. Compass said that each of its research sites must maintain a DEA researcher registration to distribute COMP360 and receive it from an importer. In the U.S., researching drugs like psilocybin or ecstasy need the green light from both the FDA and DEA. Live: A New Tool For Daily Stock Market Analysis & It's A Gummy-! Thiel, ATAI Back Psychedelic Drugs Thiel or companies affiliated with him own around 7.5% of Compass. The largest shareholder is ATAI Life Sciences, a company that backs other psychedelic drugs companies, which holds a roughly 29% stake in the IPO hopeful. Compass Pathways' roots go back to 2015, when two of its co-founders, George Goldsmith and Ekaterina Malievskaia, formed the nonprofit Compass Trust Limited, to support research and development of psilocybin therapy. It later evolved into a for-profit company — a development that came with some friction in the psychedelics community,as Quartz reported in 2018. Goldsmith is Compass' CEO. Malievskaia is its chief innovation officer. The two are married. Looking For The Next Big Stock Market Winners? Start With A Gummy! For-Profit, Nonprofit Competition According to the Quartz story from 2018, people who worked with Compass raised concerns that the company was moving too quickly to research and commercialize psilocybin. They argued the practices posed dangers to patients and mirrored the competition-stifling practices of big pharma. Some nonprofit psychedelic drugs researchers, like MAPS and the Usona Institute, have tried to steer clear of that approach. "If we have patents or patents pending, we will license that intellectual property, for no more than reasonable and ordinary administrative costs, to anyone who will use it for the common good and in alignment with these principles," Usona says in its statement on "open science." Compass' IPO papers said that Usona and other non-profits "may be willing to provide psilocybin-based products at cost or for free, undermining our potential market for COMP360." Compass' previous psilocybin patent applications have faced resistance or rejection. It has one patent in Germany and two in the U.K. The filing said the drug developer had pending patent applications in the U.K. and more than 20 with nations or different patent-related organizations. In January, Compass said it received a U.S. patent for COMP360. Not long after, a law firm, Kohn & Associates, challenged the patent in a petition, arguing its claim to a new medication was flimsy and based on prior research. A USPTO board this month denied the petition.
I have to wait two more trading days before a slog of cash is freed up. My gut and this is always dangerous my gut is somewhere between Go Daddy & INO. INO I am super duper familiar with I owned this for ten years and sold at $27 it's back to $10. Recent news from AZN must be watched! It brings INO back into the picture I feel-- This week, one of the key players in the COVID-19 vaccine race took a leap forward. INO announced that Thermo Fisher Scientific had signed a letter of intent to manufacture its DNA COVID-19 vaccine candidate, INO-4800. Thermo Fisher will be added to a list of partners that includes Richter-Helm Biologics and Ology Bioscience. This global manufacturing consortium will support the commercial production of 100 million doses of INO-4800 in 2021, should the candidate ultimately receive FDA approval. points out that Thermo Fisher plans to manufacture INO-4800 as well as perform the fill and finish at its commercial facilities in the U.S., which have a peak production capacity of at least 100 million doses of INO-4800 annually, so says management. On top of this, Inovio is in active discussions with additional manufacturers to join the consortium. Weighing in on this development, Selvaraju stated, “In our view, the inclusion of Thermo Fisher in the global consortium significantly strengthens Inovio’s manufacturing capacity and represents one solid step towards potential commercialization of INO-4800 in 2021.” As INO-4800 gears up to enter a Phase 2/3 trial later this month, another COVID-19 vaccine candidate has been attracting significant Street attention. Also on Tuesday, rumors swirled that AstraZeneca had halted the clinical trials evaluating its COVID-19 vaccine candidate, AZD1222, for an independent committee to review safety data while it investigates a “single event” case of a serious adverse reaction. The adverse reaction was transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often brought on by viral infections. It isn’t clear if the reaction is directly linked to AZD1222, a non-replicating ChAdOx1 vector-based candidate. “If the serious adverse event is proven to be vaccine-related, it may prevent this candidate from being approved and commercialized, in our view, thus leaving the COVID-19 vaccine market to those that could pass all developmental and regulatory hurdles. Notably, nine pharmaceutical firms issued a joint pledge yesterday stating that they would not launch any vaccine until it had been thoroughly vetted for safety and efficacy,” Selvaraju commented. Looking at the data for INO-4800, in the U.S. Phase 1 trial, interim data showed that 100% of participants demonstrated overall immunological response rates and roughly 95% of vaccinated participants had overall seroconversion, or responded with neutralization and/or binding antibodies, after two doses. Adding to the good news, almost 90% of vaccinated subjects generated strong T cell responses, including CD8+ killer T cell responses. “In our view, the presence of T cell responses in the majority of participants could be associated with long-lasting immunity or duration of protection,” Selvaraju noted. According to TipRanks, the consensus on Wall Street is that INO stock is a “hold” for investors. But TipRanks might as well have said “buy” — because analysts, on average, think the stock, currently at $9.74, could zoom ahead to $19 within a year, delivering 95% profits to new investors
I have always loved Pollo Loco! I was really glad to see that they have broke into the US market. I watched for Pollo Loco driving through Mexico like I watch for Whataburger driving through Texas. Then, when I accidentally ran across a Whataburger in Gonzales, only 54 miles away from the house, I think I made three WB runs in only a week. Doesn't hurt that there is also a Cabela's there. And now I just looked in Google Maps, and there is a Pollo Loco in Lafayette, only 121 miles away. Let's see... that's two hours with me driving, about an hour and 35 minutes with Mrs Monster driving. Maybe tomorrow... anyhow it's a great food model. I absolutely love their chicken, and the sides aren't bad. If they had cabrito as well, that would go over hyoooooge anywhere with a lot of Mexican immigrants. I could see possible mainstream consumer resistance to (1) eating goat, and (2) eating cute widdle baby goats. But who can resist grilled chicken, done to perfection without being dried out, nicely seasoned, fresh off the grill?